Table 4

Comparison of results for association of TNF antagonists with individual and composite cardiovascular endpoints

EndpointNo of events (N)HR95% CI
Composite endpoint (including cardiovascular deaths)820.390.19 to 0.82
Composite endpoint (excluding cardiovascular deaths)660.350.16 to 0.74
Non-fatal MI250.240.06 to 0.95
Non-fatal TIA/stroke410.440.18 to 1.09
  • All HR reflect fully adjusted models for each endpoint, adjusting for age, gender, smoking status, diabetes, hypertension, dyslipidaemia, previous myocardial infarction (MI) or stroke, modified health assessment questionnaire score, naproxen use, non-selective non-steroidal anti-inflammatory drug use and cyclooxygenase-2 inhibitor use.

  • TIA, transient ischaemic attack; TNF, tumour necrosis factor.